0001104659-20-033109.txt : 20200313
0001104659-20-033109.hdr.sgml : 20200313
20200313160640
ACCESSION NUMBER: 0001104659-20-033109
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200101
FILED AS OF DATE: 20200313
DATE AS OF CHANGE: 20200313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoenlein Malcolm
CENTRAL INDEX KEY: 0001294517
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35366
FILM NUMBER: 20712683
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205157386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
4
1
tm2011481-2_form4.xml
FORM 4
X0306
4
2020-01-01
0
0001429260
Fortress Biotech, Inc.
FBIO
0001294517
Hoenlein Malcolm
C/O FORTRESS BIOTECH, INC.
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK
NY
10014
1
0
0
0
Common Stock
2020-01-01
4
A
0
50000
0
A
385000
D
One-third of the shares will vest on each January 1, 2021, 2022 and 2023, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
The total holdings include 250,000 shares underlying deferred restricted stock units.
/s/ Samuel Berry / Attorney-in-Fact
2020-03-13